Archive: Company News
Company News: Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that the Company is going to attend several industry conferences in the third quarter of 2017. The respective presentations will be made available on the company’s website.
Company News: Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME
– First-ever clinical study demonstrates personalized RNA-based vaccine using mutant neo-epitopes as antigens activates immune system against individual mutations and exerts anti-cancer activity –
BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced Phase I trial results demonstrating its IVAC® MUTANOME, an individualized RNA vaccine based on patient-specific mutations, induces strong immunogenicity as well as promising anti-tumor activity in high-risk patients with late-stage melanoma.
Company News: Agena Bioscience Launches CE-IVD System For Hospitals And Diagnostic Laboratories In Europe
– MassARRAY® System with Chip Prep Module receives CE-IVD marking for general in vitro diagnostic use in Europe
Agena Bioscience today announced the European launch of the MassARRAY® System with CHIP Prep Module (CPM), marketed as a CE-IVD product under the Directive 98/79/EC for in vitro diagnostic medical devices.
Company News: “GEAR – Predicting Antibiotic Resistances with Genetic Data” Succeeds in Competition “Landmarks in the Land of Ideas”
Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH and a developer of pioneering solutions for the detection of genetic resistances in pathogens, today announced that the project “GEAR – Predicting Antibiotic Resistances with Genetic Data” has been awarded in the competition “Landmarks in the Land of Ideas”.